3333 Michelson Drive
Suite 650
Irvine, CA 92612
United States
805 562 3500
https://sientra.com
Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 304
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Ronald Menezes | President, CEO & Director | 501.18k | N/A | 1963 |
Mr. Andrew C. Schmidt | Senior VP, Treasurer & CFO | 365.4k | N/A | 1961 |
Mr. Oliver Christian Bennett | Senior VP, Chief Legal, Compliance, & Corporate Development Officer | 363.37k | N/A | 1977 |
Mr. Keith J. Sullivan | Advisor to MiraDry Business | 40k | N/A | 1958 |
Ms. Caroline F. Van Hove | Executive Chair of Board of Directors | 197.74k | N/A | 1981 |
Dr. Denise Dajles | Chief Technical Officer | N/A | N/A | N/A |
Mr. Mark S. Saxton | Senior Vice President Sales | N/A | N/A | 1965 |
Ms. Adelle Walker | Senior Vice President of Corporate Strategy & Marketing | N/A | N/A | N/A |
Mr. Matt Hostetler | Chief People Officer | N/A | N/A | N/A |
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides fat transfer systems; body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists, and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Irvine, California. On February 12, 2024, Sientra, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Sientra, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 8; Compensation: 9.